1997 Fiscal Year Final Research Report Summary
Basic and clinical research of treatment for ocular disease by KANPO-drugs
| Project/Area Number |
08672011
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Ophthalmology
|
|---|
| Research Institution | TOYAMA MEDICAL AND PHARMACEUTICAL UNIVERSITY |
|---|
Principal Investigator |
HAYASAKA Seiji TOYAMA MEDICAL & PHARMACEUTICAL UNIVERSITY,MEDICINE,PROFFESOR, 医学部, 教授 (00004961)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KITAGAWA Kiyotaka TOYAMA MEDICAL & PHARMACEUTICAL UNIVERSITY,MEDICINE,RESEARCH ASSOCIATE, 医学部, 助手 (00270950)
HIRAKI Shigeyoshi TOYAMA MEDICAL & PHARMACEUTICAL UNIVERSITY,HOSPITAL,ASSISTANT PROFFESOR, 附属病院, 講師 (40181151)
|
|---|
| Project Period (FY) |
1996 – 1997
|
| Keywords | KANPO-DRUG / KAKKON-TO / SAIREI-TO / PROSTAGLANDIN E_2 / ENDOTOXIN (LIPOPOLYSACCHARIDE) / INTRAOCULAR INFLAMATION / UVEITIS / AQUEOUS FLARE |
|---|
| Research Abstract |
1. Basic research
We investigated the effects of KANPO-druds for experimental uveitis. we report the results of new evidence acquired from the experiments.
(1) The effects of KANPO-druds for experimental uveitis induced by topical prostaglandin E_2 KANPO-druds of ten-fold doses of human clinical dose were adiministered for 1 week before prostaglandin E_2 (10mug/ml) -treatment.
The KANPO-druds of SAIREI-TO,KAKKON-TO and ORENGEDOKU-TO,respectively, did not inhibited the experimental uveitis.
(2) The effects of KANPO-druds for experimental uveitis induced by lipopolysaccaharide
(1) KAKKON-TO of five-fold doses of human clinical dose were administered for 1 week before lipopolysaccharide (0.5mug/kg) -treatment. But, the experimental uveitis were not inhibited.
(2) SAIREI-TO were administered for 1 week before lipopolysaccharide (0.5mug/kg) -treatment. In ten-fold and three-fold doses of human clinical dose of SAIREI-TO,the experimental uveitis were significantly inhibited compared with control.
|
